NCT04082832 is a Phase 2, PHASE3 clinical trial of Cu(II)ATSM in Amyotrophic Lateral Sclerosis, sponsored by Collaborative Medicinal Development Pty Limited.

Who is sponsoring NCT04082832?

NCT04082832 is sponsored by Collaborative Medicinal Development Pty Limited.

What drugs are being tested in NCT04082832?

Interventions in NCT04082832: Cu(II)ATSM, Placebos.

What condition does NCT04082832 study?

NCT04082832 studies Amyotrophic Lateral Sclerosis.

Is NCT04082832 still recruiting?

NCT04082832 is currently status unknown. Last updated 6 November 2019.

Last reviewed 2019-11-06 · How we verify

NCT04082832

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CuATSM Compared With Placebo for Treatment of ALS/MND

Status unknown Phase 2, PHASE3 Last updated 6 November 2019

What this trial tests

Phase 2, PHASE3 trial testing Cu(II)ATSM in Amyotrophic Lateral Sclerosis in 80 participants. Status unknown.

Timeline

30 September 2019

Primary endpoint
30 December 2020

30 December 2020

Quick facts

Lead sponsor	Collaborative Medicinal Development Pty Limited
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	80
Start date	30 September 2019
Primary completion	30 December 2020
Estimated completion	30 December 2020
Sites	1 location across Australia

Drugs / interventions tested

Cu(II)ATSM — full drug profile →
Placebos — full drug profile →

Conditions studied

Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →

Sponsor

Collaborative Medicinal Development Pty Limited — full company profile →

Who can join

Adults 18 to 75, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and efficacy of CuATSM in patients with ALS/MND. Patients will be randomized 1:1 to CuATSM or placebo for 6 x 28-day cycles (24 weeks) of treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular mechanisms of cell death in neurological diseases.
Moujalled D, Strasser A, Liddell JR. · · 2021 · cited 513× · PMID 34099897 · DOI 10.1038/s41418-021-00814-y
Copper Dyshomeostasis in Neurodegenerative Diseases-Therapeutic Implications.
Gromadzka G, Tarnacka B, Flaga A, Adamczyk A. · · 2020 · cited 226× · PMID 33291628 · DOI 10.3390/ijms21239259
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease.
Nguyen TT, Wei S, Nguyen TH, Jo Y, et al · · 2023 · cited 221× · PMID 37612409 · DOI 10.1038/s12276-023-01046-5
Getting out what you put in: Copper in mitochondria and its impacts on human disease.
Cobine PA, Moore SA, Leary SC. · · 2021 · cited 197× · PMID 32979421 · DOI 10.1016/j.bbamcr.2020.118867
Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic.
Trist BG, Hilton JB, Hare DJ, Crouch PJ, et al · · 2021 · cited 148× · PMID 32144830 · DOI 10.1002/anie.202000451
Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant?
Bisaglia M, Bubacco L. · · 2020 · cited 147× · PMID 32013126 · DOI 10.3390/biom10020195
Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance.
Ayton S, Portbury S, Kalinowski P, Agarwal P, et al · · 2021 · cited 145× · PMID 33491917 · DOI 10.1002/alz.12282
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases.
Chen L, Shen Q, Liu Y, Zhang Y, et al · · 2025 · cited 119× · PMID 39894843 · DOI 10.1038/s41392-024-02071-0

Verify or expand the search:

Other trials of Cu(II)ATSM

Trials testing the same drug.

NCT04313166 — Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 · Phase 2 · completed
NCT03136809 — ALS Treatment Extension Study · Phase 1, PHASE2 · unknown
NCT03204929 — Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease · Phase 1 · completed
NCT02870634 — Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND · Phase 1 · completed

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting

Other Collaborative Medicinal Development Pty Limited trials

Trials by the same sponsor.

NCT04313166 — Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 · Phase 2 · completed
NCT03136809 — ALS Treatment Extension Study · Phase 1, PHASE2 · unknown
NCT03204929 — Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease · Phase 1 · completed
NCT02870634 — Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND · Phase 1 · completed
NCT02688101 — Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04082832 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Collaborative Medicinal Development Pty Limited
Last refreshed: 6 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04082832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing